Centers for AIDS Research (CFAR)

描述(由申请人提供)：杜克大学艾滋病研究中心(CFAR)的主要使命是通过支持杜克大学基础和临床艾滋病毒/艾滋病研究社区的科学需求，促进与艾滋病相关的研究的合作和协调。在这一竞争性续签申请中，新的杜克大学CFAR寻求利用其在医学中心内新建立的领导角色，在其存在的头4年的许多重要成就的基础上，进一步扩大整体基础设施和方案支持，这些支持将继续提供具有成本效益的最先进的基本服务，同时也是杜克大学未来艾滋病毒/艾滋病合作研究计划的催化剂。非常成功的小额赠款支助机制以及积极招聘5名新的关键艾滋病毒/艾滋病调查员到杜克大学工作，都为进入下一个供资周期奠定了坚实的基础。通过高效的战略规划过程，杜克大学癌症研究中心领导层与杜克大学癌症研究中心外部咨询委员会协商，确定了未来5年发展和支持的4个优先领域，这些领域包括1)与杜克大学癌症综合研究所(DCCI)合作在杜克大学创建与艾滋病相关的恶性肿瘤基础和临床研究计划，2)开发和支持一个全面的临床数据库和链接标本储存库，3)通过有针对性的癌症研究中心和教师招聘支持，从计划上关注艾滋病毒的致病机制和消除病毒库，以及4)通过与杜克大学癌症研究中心的整合，让人类基因组学领导层充分参与校园工作。CFAR-DCCI关于AIM 1的联合倡议得到了DCCI主任提供的慈善配对资金的进一步证实。在新资金的最初一年，Duke CFAR服务核心将开始作为“部分”共享资源运营，由折扣服务费和减少的CFAR投资支持，从而腾出资金，用于在出现新的需求和机会时进一步扩大CFAR核心和服务。除了其整体的基础设施支持，新的杜克CFAR现在牢牢地确立了杜克大学公认的领导地位，并在医疗中心的关键决策过程中占据了一个非常重要的“谈判桌”。CFAR领导层期待着在NIH未来5年的资金支持下，为杜克大学的艾滋病毒/艾滋病研究界提供更好的服务和支持。

DESCRIPTION (provided by applicant): The principal mission of the Duke Center for AIDS Research (CFAR) is to promote the collaboration and coordination of AIDS-related research by supporting the scientific needs of the basic and clinical HIV/AIDS research community at Duke. In this competitive renewal application, the new Duke CFAR seeks to use its newly established leadership role within the Medical Center to build upon the many important accomplishments of its first 4 years in existence and, in doing so, to further expand the overall infrastructure and programmatic support that will continue to provide cost effective state of the art essential services while also serving as a catalyst for future HIV/AIDS collaborative research initiatives at Duke. The highly successful Small Grant support mechanism as well as the active recruitment of 5 new key HIV/AIDS investigators to Duke both form a solid basis in moving forward into the next funding cycle. Through a highly effective Strategic Planning process, the Duke CFAR leadership, in consultation with the Duke CFAR External Advisory Committee has identified 4 priority areas for development and support over the next 5 years, that comprise the Specific Aims for this proposal and include 1) creation of an AIDS-associated malignancies basic and clinical research program at Duke in collaboration with the Duke Comprehensive Cancer Institute (DCCI), 2) development and support of a comprehensive clinical database and linked specimen repository, 3) programmatic focus on HIV pathogenesis and elimination of viral reservoirs through targeted RFAs and faculty recruitment support, and 4) full engagement of the human genomics leadership on campus through integration with the Duke CFAR. The joint CFAR-DCCI initiative for Aim 1 is further substantiated by philanthropic matching funds made available by the DCCI Director. During the initial year of new funding, the Duke CFAR service Cores will begin operating as 'partial' shared resources supported by discounted service fees and reduced CFAR investment, thus freeing funds for use in further expansion of the CFAR Cores and services as emerging needs and opportunities arise. In addition to its overall infrastructure support, the new Duke CFAR is now firmly entrenched in a highly-recognized leadership position at Duke and occupies an all important 'seat at the table' in the critical decision-making processes within the Medical Center. The CFAR leadership looks forward to providing enhanced services and support to the Duke HIV/AIDS research community in conjunction with the next 5 years of NIH funding.